Oxanabol Tablets
Oxanabol Tablets British Dragon — Overview
Oxanabol Tablets deliver oxandrolone at 10 mg per tablet — the compound marketed for decades under the brand name Anavar and widely considered the most versatile mild oral AAS available. Oxandrolone is a 17α-alkylated dihydrotestosterone derivative with a structural modification unique among oral AAS: the oxygen substitution at position 2 of the A-ring (replacing a carbon atom) makes it resistant to 3α-hydroxysteroid dehydrogenase inactivation in muscle tissue. This is the structural reason oxandrolone retains genuine anabolic activity in muscle despite being a DHT derivative — the same structural class that produces compounds like mesterolone, which 3α-HSD inactivates in muscle before it can build tissue.
The result is an oral AAS that combines dry anabolic output — lean muscle retention, strength gains, nitrogen retention — with an absence of estrogenic effects, a notably milder hepatotoxic profile than most 17α-alkylated orals, and a lower androgenic burden than testosterone-based compounds. It does not produce water retention, does not aromatize, and can be run for up to 8 weeks in male protocols — longer than most oral AAS. steroidwarehouse.com stocks Oxanabol as part of the British Dragon oral lineup for cutting cycles, strength protocols, and female use.
About the Compound
Oxandrolone's structural foundation is dihydrotestosterone with two modifications: the standard 17α-methyl group that enables oral bioavailability, and the substitution of an oxygen atom for the C2 carbon in the A-ring. The 17α-methyl group produces hepatotoxicity — as with all 17α-alkylated orals — but the oxandrolone molecule is metabolized more slowly than most of its structural class, producing a longer half-life (~9–10 hours) and less acute hepatic burden per milligram of dose. Clinical studies in patient populations have run oxandrolone at 20 mg/day for up to 12 weeks with acceptable liver enzyme profiles — a duration that would be contraindicated for methandienone or oxymetholone at comparable relative doses.
The 2-oxa modification (oxygen at position 2) is what distinguishes oxandrolone from simple DHT derivatives like mesterolone. Mesterolone is rapidly inactivated by 3α-HSD in muscle tissue; oxandrolone's A-ring modification makes it a poor substrate for that enzyme, allowing it to persist in muscle tissue and activate androgen receptors at meaningful levels. This is the structural basis for oxandrolone's genuine anabolic activity — not primarily mass-building in a wet sense, but lean tissue retention and nitrogen balance maintenance, particularly during caloric restriction.
The ~9–10 hour half-life is significantly longer than methandienone (~3–6 hours) and allows once-daily dosing, though twice-daily dosing is preferred at higher doses to maintain more consistent plasma levels and spread the daily hepatic load.
What Oxandrolone Does
Oxandrolone's anabolic output operates through androgen receptor activation in muscle tissue — a pathway that is preserved specifically because the 2-oxa modification protects the molecule from the 3α-HSD inactivation that eliminates most DHT-class compounds in muscle. The downstream effects are distinctly different from aromatizing mass builders:
- Lean muscle retention and nitrogen balance — oxandrolone produces a positive nitrogen balance at doses as low as 20 mg/day. In a caloric deficit, this nitrogen retention effect is particularly valuable: it slows the rate of lean tissue catabolism that normally accompanies cutting, preserving muscle mass while fat loss proceeds. This is the mechanism behind its established clinical use in catabolic states — burn patients, HIV wasting, post-surgical recovery — and its performance application in cutting cycles.
- Strength gains without mass accumulation — oxandrolone produces meaningful strength increases that are disproportionate to the amount of lean mass gained. The mechanism involves both AR-mediated muscle contractile protein synthesis and enhanced phosphocreatine synthesis — an effect documented specifically for oxandrolone and not universally shared by all oral AAS. This makes it particularly suited to strength-sport athletes competing in weight classes, where gaining bodyweight is a competitive disadvantage.
- No estrogen-related effects — oxandrolone does not aromatize and produces no estrogenic metabolites. Water retention is essentially absent at any practical dose. The visual result during a cycle is a dry, hard appearance as the anabolic effect of the compound operates without the subcutaneous water accumulation that accompanies aromatizing AAS.
- Mild androgenicity — relative to testosterone, oxandrolone's androgenic activity in skin and scalp tissue is meaningfully lower. The 2-oxa modification slightly reduces 5α-reductase affinity compared to standard DHT, further limiting androgenic side effects in androgen-sensitive peripheral tissues. At 40 mg/day, androgenic sides are considerably less pronounced than at equivalent doses of stanozolol or methandienone.
Who It Is For
Oxandrolone's profile suits users who need anabolic support — lean muscle maintenance, nitrogen retention, strength — without the estrogenic and mass-gaining consequences of aromatizing compounds, and without the full androgenic burden of stronger dry orals like stanozolol or fluoxymesterone.
- Cutting cycle users preserving muscle during a caloric deficit — the primary male performance use. At 40–60 mg/day during a cutting phase, oxandrolone maintains nitrogen balance against the catabolic pressure of the deficit, reducing muscle loss while fat is being shed. The dry, no-water profile means the compound contributes to the leanness of the appearance rather than masking it. It pairs cleanly with a testosterone base for hormonal support during the cut.
- Strength athletes competing in weight classes — combat sport athletes, powerlifters, and Olympic weightlifters who need strength gains without bodyweight increase benefit specifically from oxandrolone's phosphocreatine and strength-without-mass profile. At 20–30 mg/day, the compound produces strength improvements within 2–3 weeks without the water weight that would push a competitor into a heavier class.
- Female users seeking lean anabolic support — oxandrolone is the most widely used oral AAS in female protocols because its low androgenicity at 5–10 mg/day produces meaningful muscle retention and performance benefits with a low risk of virilization. Women are significantly more sensitive to androgens than men; the 10 mg tablet allows precise dosing at 5 mg (half-tab) or 10 mg per day — the range where female benefit is well-documented and virilization risk is manageable.
Choose something else when: maximum mass gain is the goal — oxandrolone's anabolic output does not produce the rapid mass accumulation of aromatizing orals like methandienone; use Methanabol 10 for mass cycles instead. When a strong cosmetic hardening and vascularity effect is needed alongside strength, Stanabol Tablets BD (stanozolol) produces a more dramatic visual result at the cost of greater joint dryness and higher androgenicity.
Oxanabol vs Alternatives
| Compound | Key Differences | Choose Oxanabol When | Choose Alternative When |
|---|---|---|---|
| Oxanabol Tablets British Dragon |
Oxandrolone 10 mg/tab; dry, no aromatization; lean muscle and strength without water; milder hepatotoxicity than most oral AAS; lowest androgenicity in the dry oral class; female-compatible; 6–8 week cycle possible for men | Cutting cycle lean muscle retention; strength without bodyweight gain; female AAS protocol; mild androgenic profile required | — |
| Stanabol Tablets British Dragon |
Stanozolol 10 mg/tab; also dry, no aromatization; stronger cosmetic hardening and vascularity effect; greater androgenicity; more pronounced SHBG binding than oxandrolone; notable joint dryness at higher doses; harsher hepatic profile | Strong visual hardening and vascularity in lean conditions; more aggressive androgenic response desired; cosmetic pre-contest dry look | Milder androgenic profile required; female use; joint issues at risk; longer cycle duration needed → Oxanabol |
| Methanabol 10 British Dragon |
Methandienone 10 mg/tab; strong aromatizer; rapid mass and water gain; glycogenolysis-driven strength; wet appearance; 4–6 week limit; significantly higher estrogenic load requiring active AI management | Maximum mass and strength within weeks; kickstart role on a mass cycle; wet gains acceptable | Dry lean output, cutting cycle, or female use → Oxanabol |
| Mesterolone Tablets British Dragon |
Mesterolone 25 mg/tab; non-17α-alkylated — no hepatotoxicity; SHBG binder and free testosterone booster; no direct muscle anabolic effect (3α-HSD inactivation in muscle); adjunct and support compound, not a mass or strength builder | Direct anabolic output needed — lean muscle and strength → Oxanabol; mesterolone does not build muscle | SHBG displacement and free T support needed with zero hepatic load; libido support during PCT → Mesterolone |
Combinations
| Goal | Stack | Why It Works |
|---|---|---|
| Classic cutting cycle | Testabol Propionate BD (100 mg EOD, weeks 1–10) + Oxanabol (40–60 mg/day, weeks 5–10) + Anastrozole BD (0.25 mg EOD) + Liv52 (weeks 5–10) | Testabol Propionate provides testosterone support and a lean anabolic base with fast ester clearance — appropriate for a cutting phase where cycle timing matters. Oxanabol is added in the back half of the cycle when caloric restriction is in full effect, directly countering the catabolic pressure with nitrogen retention and lean muscle support. Anastrozole at low frequency manages any E2 from propionate without overcorrecting. The dry outputs from both compounds are complementary — no estrogenic water from either. |
| Strength protocol — weight-class athletes | Testabol Enanthate BD (200–300 mg/wk, weeks 1–12) + Oxanabol (20–30 mg/day, weeks 1–8) + Anastrozole BD (0.25 mg EOD) + Liv52 (weeks 1–8) | Low-dose testosterone enanthate maintains androgen background and HPG suppression coverage without driving significant mass gain. Oxanabol's phosphocreatine-related strength effect operates independently of weight gain — users in weight-sensitive sports get the strength benefit without the water and mass that higher-dose aromatizing compounds would impose. The 20–30 mg oxandrolone range at this combination point produces strength gains with minimal water contribution from either compound at these conservative testosterone doses. |
| Female lean cycle | Oxanabol (5–10 mg/day, weeks 1–6) — standalone or alongside very low-dose Testabol Propionate (25–50 mg/wk at most, if injectable support is specifically desired) | At 5–10 mg/day, oxandrolone provides meaningful nitrogen retention and lean muscle support in female users. The 10 mg tablet allows dosing at 5 mg (half tablet) for the first 2 weeks as a tolerance test before stepping to 10 mg/day. The primary risk to monitor is androgenic virilization — voice changes, clitoral sensitivity, and facial hair — which are dose-dependent and generally avoided at this dose range in 4–6 week cycles. Unlike most AAS, the risk-to-benefit ratio at these doses in female users is well-documented and broadly favorable. |
Side Effects & Management
| What May Occur | Background | How to Handle It |
|---|---|---|
| Hepatotoxicity — liver enzyme elevation | Oxandrolone is 17α-alkylated and therefore hepatotoxic. Its hepatic burden is consistently documented as lower than methandienone, oxymetholone, and stanozolol at equivalent relative doses — a property attributed to slower hepatic metabolism and different metabolite profiles. ALT/AST elevation occurs but is generally less pronounced; cycles up to 8 weeks at 40–60 mg/day are used in male protocols with acceptable liver panel outcomes in healthy users. Zero alcohol during the cycle, regardless of the compound's relative tolerability. | Liver support throughout the cycle: Liv52. Mid-cycle ALT/AST at week 4. Above 3× ULN: reduce dose. Above 5× ULN: discontinue. No alcohol. |
| Lipid disruption — HDL suppression | Despite its relatively mild overall side effect profile, oxandrolone produces a notable HDL suppression that is disproportionate to its other effects. Studies at 20 mg/day have documented HDL reductions of 30–50% — a more pronounced lipid impact than its androgenic side effect burden might suggest. This is the most clinically significant ongoing concern with oxandrolone use, particularly for longer 6–8 week cycles where the cumulative lipid disruption is greater. | Lipid panel at baseline and mid-cycle (week 4 for 6–8 week cycles). Elevated LDL: Atorlip (atorvastatin). Blood pressure if HDL suppression combines with dietary factors to elevate cardiovascular risk: Amlip (amlodipine). Omega-3 supplementation and reduced saturated fat intake support HDL during the cycle. |
| Androgenic effects — acne, hair loss | Oxandrolone's androgenicity is lower than testosterone and most other oral AAS, but not zero. At 40–60 mg/day, predisposed users can experience oily skin, acne (typically milder than with methandienone or stanozolol), and some degree of androgenetic hair loss acceleration. In female users, androgenic virilization — voice deepening, clitoral sensitivity, facial hair — is the primary risk and is dose- and duration-dependent. | Persistent acne: Isotroin (isotretinoin). Female users: any early virilization sign warrants immediate dose reduction or discontinuation — some effects (voice changes) are not fully reversible if the compound is continued after onset. |
| HPG axis suppression | Oxandrolone suppresses LH and FSH, reducing endogenous testosterone production. Suppression is mild to moderate at 20–30 mg/day and more complete at 60+ mg/day. The milder suppression relative to injectable AAS or methandienone means recovery is generally faster and more complete after a cycle, but PCT is still appropriate for cycles over 4 weeks at any dose above 20 mg/day in men. Women naturally do not have the same recovery concern but should allow equivalent recovery time between cycles. | Always pair with a testosterone base for male cycles over 4 weeks to prevent hypogonadal symptoms from suppression. Full PCT (Clomiphene + Tamoxifen) after any male cycle. See PCT section below. |
Bloodwork Monitoring
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| ALT / AST (liver enzymes) | Baseline; week 4 (mid-cycle for 6–8 week runs); 4 weeks post-cycle | Within 2× ULN during use. Above 3× ULN: reduce dose. Confirm return to baseline at 4 weeks post-cycle. Oxandrolone's milder hepatic profile means some users see only minor elevation at 40 mg/day, but do not skip the mid-cycle check — longer cycle duration accumulates hepatic burden even at lower per-dose levels. |
| Lipid panel (HDL / LDL / total cholesterol) | Baseline; week 4; 6 weeks post-cycle | HDL above 35 mg/dL; LDL below 130 mg/dL. Oxandrolone's HDL suppression is its most significant ongoing lipid concern — at week 4, a reading below 35 mg/dL warrants Atorlip and dietary adjustment. Confirm lipid recovery 6 weeks post-cycle. |
| Hematocrit / CBC | Baseline; mid-cycle | Hematocrit below 52%. Oxandrolone has mild erythropoietic activity; at higher doses or when combined with testosterone, hematocrit monitoring is warranted. |
| Blood pressure | Every 2–3 weeks during the cycle | Below 130/80 mmHg. Oxandrolone does not drive significant E2-mediated water retention; BP elevation is less common than with aromatizing AAS. Monitor nonetheless — HDL suppression and any lipid impact can contribute to cardiovascular risk over a longer cycle. |
| LH + FSH | Baseline; 4 weeks post-PCT | Confirm gonadotropin recovery to pre-cycle baseline. Oxandrolone's milder suppression typically allows full recovery within 3–5 weeks post-PCT — faster than after heavy injectable cycles. |
PCT — Post-Cycle Therapy
Oxandrolone suppresses the HPG axis in male users at any dose above 20 mg/day for more than 3–4 weeks. The degree of suppression is milder than with testosterone-based injectables or methandienone, and recovery tends to be faster — but PCT remains appropriate after any meaningful male oxandrolone cycle to restore endogenous testosterone production efficiently rather than waiting for spontaneous recovery.
PCT begins 3–5 days after the last oxandrolone tablet (the ~9–10 hour half-life clears the compound quickly). If oxandrolone was used as part of a stack with a long-ester injectable, PCT timing is set by the injectable's clearance.
| Product | Role |
|---|---|
| Clomiphene Tablets BD | 50 mg/day weeks 1–2, then 25 mg/day weeks 3–4. LH/FSH stimulant. Oxandrolone's milder suppression means some users need only a 3-week PCT at these doses; confirm by post-PCT LH/FSH bloodwork. |
| Tamoxifen Tablets BD | 20 mg/day weeks 1–2, then 10 mg/day weeks 3–4. Hypothalamic SERM. Run concurrently with Clomiphene. Since oxandrolone does not aromatize, residual estrogen during recovery is less of a concern than after aromatizing cycles — Tamoxifen's primary role here is gonadotropin recovery support, not gynecomastia prevention. |
Practical Summary
- Dry output only — no AI needed for oxandrolone itself: oxandrolone does not aromatize and produces no estrogenic effects at any dose. An AI is only needed if oxandrolone is stacked with an aromatizing injectable (testosterone, boldenone). Running oxandrolone standalone does not require an aromatase inhibitor — a meaningful practical simplification compared to most AAS cycles.
- Lipids require closer attention than liver at this dose: the disproportionate HDL suppression is oxandrolone's most significant ongoing risk at standard doses — more so than its liver enzyme elevation, which is milder than with other oral AAS. The mid-cycle lipid check at week 4 is not optional on a 6–8 week cycle.
- Once or twice daily dosing — not three times: the ~9–10 hour half-life allows once-daily dosing, though twice daily spreads the hepatic load and maintains more consistent blood levels at higher doses. Three-times-daily dosing as used with methandienone is unnecessary and adds no benefit at this half-life.
- Women: start at 5 mg/day for 2 weeks before stepping to 10 mg: the 10 mg tablet can be halved. Individual androgenic sensitivity in women varies significantly — establishing a baseline response at 5 mg before committing to 10 mg is the appropriate stepwise approach. At the first sign of virilization, stop immediately: some androgenic effects in women are not fully reversible if the compound is continued after onset.
- Longer cycles are possible, not the norm — monitor accordingly: the 6–8 week male cycle window is a genuine pharmacological option, not a target. A 4–6 week cycle with a mid-cycle liver and lipid check is appropriate for most users. The longer window is for those who specifically need extended anabolic support (deep cutting phases, extended lean protocols) and have confirmed good hepatic tolerance from a prior cycle.
- PCT starts 3–5 days post-last tablet: oxandrolone's half-life means it clears within 2–3 days of the last dose. There is no ester-related clearance delay — PCT begins almost immediately after the cycle ends, making the recovery timeline faster than after injectable AAS cycles.
Oxanabol Tablets stand apart from every other oral AAS in the British Dragon catalog by combining genuine anabolic activity, a dry lean output, milder hepatotoxicity, and the lowest androgenic burden in the class — a profile that extends its practical application across cutting cycles, strength sports, and female protocols that no other oral AAS covers as cleanly. Steroid Warehouse carries Oxanabol as part of the full British Dragon oral range.
References
| Source | Description | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial evaluating 600 mg/week testosterone enanthate in healthy men with and without resistance training; demonstrated significant increases in fat-free mass, muscle size, and strength, establishing the anabolic effects of supraphysiologic testosterone administration | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on synthetic testosterone-derived anabolic-androgenic steroids, androgen receptor activity, oral and injectable forms, adverse effect profiles, misuse patterns, and monitoring considerations | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — comprehensive overview of testosterone, dihydrotestosterone, androgen receptor signaling, HPG-axis regulation, synthetic androgen pharmacology, aromatization, and endocrine suppression associated with exogenous androgen use | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| British Journal of Pharmacology / PubMed | Kicman AT 2008 — comprehensive review of anabolic-androgenic steroid pharmacology; covers androgen receptor binding, steroid metabolism, structural modification, ester pharmacokinetics, anabolic and androgenic mechanisms, detection methods, and adverse effects associated with AAS use | Kicman AT (2008) ↗ |
| Sports Medicine / PubMed | Hartgens F & Kuipers H 2004 — review of androgenic-anabolic steroid effects in athletes; covers strength and bodyweight changes, body composition, erythropoiesis, lipid profiles, cardiovascular effects, endocrine suppression, hepatic effects, and psychological considerations | Hartgens F & Kuipers H (2004) ↗ |
What is Oxanabol Tablets?
Oxanabol Tablets are an oral anabolic steroid (Oxandrolone) for lean muscle and fat loss; see What is Oxanabol Tablets. It's mild—consult professionals for safe use.
Is Oxanabol the same as Anavar?
Yes, Oxanabol is the same as Anavar, containing Oxandrolone; see Is Oxanabol the Same as Anavar. It promotes lean gains—consult professionals.
What does Oxanabol Tablets do?
It promotes lean muscle, strength, and fat loss; see What Does Oxanabol Tablets Do. It enhances definition—monitor with labs.
How long does Oxanabol stay in your system?
Detectable for ~3-4 weeks; see How Long Does Oxanabol Stay in Your System. Monitor with professional guidance.
How do I take Oxanabol Tablets?
20-50 mg/day for men, 5-20 mg/day for women, split into 2-3 doses; see How to Take Oxanabol Tablets. Start low—consult professionals for dosing.
How to cycle Oxanabol Tablets?
6-8 weeks, 20-40 mg/day, PCT after 1-2 days; see How to Cycle Oxanabol Tablets. Stack with testosterone—consult professionals for protocols.
Are Oxanabol Tablets better for bulking or cutting?
Oxanabol Tablets are most commonly associated with cutting and recomposition phases due to their reputation for supporting lean muscle preservation and physique refinement with minimal water retention.
What are the possible side effects of Oxanabol Tablets?
Potential side effects may include changes in cholesterol levels, liver stress, acne, and suppression of natural testosterone production, depending on individual response and usage patterns.
Related Products
